
News|Articles|December 13, 2012
FDA updates safety review for smoking-cessation drug
The smoking-cessation drug varenicline (Chantix, Pfizer) may increase the risk of cardiovascular adverse events, according to an updated safety review from FDA.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
What IRA drug prices will mean for PBMs, health plans and patients
2
Biosimilar competition could surpass IRA-negotiated savings by year three
3
Catheter ablation shows benefits for patients with both aFib and sleep apnea
4
Ultra-processed foods linked to early-onset colorectal adenomas in women
5





















































